← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Panorama Research, Inc.
Sunnyvale, CA
$29,434,638
Total funding
96
Grants
Funding over time
peak $2.5M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,434,638 · 96
By mechanism
R43$15,524,501 · 82
R44$13,704,209 · 13
R21$205,928 · 1
Investigators at Panorama Research, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Monoclonal antibody for autoimmune disease$905,412
R44 · FY2019 · AI
Myocardial Repair by Targeted Stem Cells$903,306
R44 · FY2008 · HL
Novel Therapy for the Common Cold$894,929
R44 · FY2002 · AI
Myocardial Repair by Targeted Stem Cells$882,950
R44 · FY2009 · HL
Novel NMDA-targeted Therapy for Alzheimer's Disease$788,076
R44 · FY2017 · AG
Rational antibody therapy for IPF$758,362
R44 · FY2018 · HL
Rational antibody therapy for IPF$735,251
R44 · FY2017 · HL
Novel NMDA-targeted Therapy for Alzheimer's Disease$710,940
R44 · FY2018 · AG
Monoclonal antibody for autoimmune disease$592,822
R44 · FY2018 · AI
Anti-inflammatory Nicotinic Agonists for Therapy of Ulcerative Colitis$570,746
R44 · FY2011 · DK
Anti-inflammatory Nicotinic Agonists for Therapy of Ulcerative Colitis$501,592
R44 · FY2010 · DK
Antibody-Membrane Switch (AMS) technology for optimized antibody engineering$499,789
R44 · FY2015 · AI
Novel Therapy for Staphylococcal Infection$482,400
R44 · FY2002 · AI
Antibody-Membrane Switch (AMS) technology for optimized antibody engineering$455,800
R44 · FY2016 · AI
Novel Therapy for the Common Cold$455,650
R44 · FY2001 · AI
Novel Immunoadhesin Molecule for Cancer Therapy$394,331
R44 · FY2006 · CA
Novel Therapy for Staphylococcal Infection$387,424
R44 · FY2001 · AI
NOVEL NMDA RECEPTOR ANTAGONISTS FOR HIV NEUROINJURY$384,099
R44 · FY2000 · MH
STABLE FOLD SELECTION FOR HETEROLOGOUS PROTEINS$375,000
R44 · FY2000 · AI
STABLE FOLD SELECTION FOR HETEROLOGOUS PROTEINS$375,000
R44 · FY2001 · AI